BMY vs EXEL
BMY: A leading biopharmaceutical innovator focused on discovering and delivering life-changing medicines to address serious illnesses globally. EXEL: Exelixis is a commercial-stage oncology biotechnology company with a strong focus on developing small-molecule treatments for various types of cancer.
Side-by-side fundamentals
| Metric | BMY | EXEL | Edge |
|---|---|---|---|
| Price as of 2026-10-08 close | $59.58 | $59.02 | |
| Market cap | $121.7B | $14.6B | |
| P/E as of 2026-10-08 | 13.12 | 18.54 | BMY lower |
| PEG as of 2026-10-08, 1-year EPS growth to FY2026 | n/a | 0.32 | |
| Net margin | +14.6% | +33.7% | EXEL higher |
| Operating margin FY2026, SEC XBRL | n/a | +37.6% | |
| ROE | +38.2% | +36.2% | BMY higher |
| ROA | +7.8% | +27.5% | EXEL higher |
| Debt / equity as of 2026-09-03 | 1.93 | 0.00 | EXEL lower |
| Revenue growth (YoY) as of 2026-09-03 | +3.1% | +9.2% | EXEL higher |
| Revenue CAGR (3y) SEC XBRL | +1.4% | +9.5% | EXEL higher |
| Dividend yield as of 2026-09-03 | +4.0% | n/a | |
| Dividend streak (yrs) SEC XBRL | 19 | 0 | BMY higher |
| Beta as of 2026-09-03 | 0.25 | 0.55 | |
| 1-year return as of 2026-10-08 close | +33.8% | +52.7% | EXEL higher |
Fundamentals: SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-03 for the rest. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-10-08.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.